BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

...least two other companies, Bolt Therapeutics Inc. and Silverback Therapeutics Inc. (NASDAQ:SBTX...
...the viral ssRNA detectors TLR7 and TLR8; Silverback’s...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...Shawver’s Silverback raises $242M, while Sigilon brings in $126M   By Paul Bonanos, Associate Editor Three more...
...aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback...
...Sanofi (Euronext:SAN; NASDAQ:SNY). OrbiMed Advisors is Silverback’s largest shareholder, with 35% before the offering.On Friday, Silverback...
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...Biotech to List on HK Main Board”).EcoR1 leads Silverback’s $85M roundInnate immune and cancer company Silverback Therapeutics Inc....
...comprising a HER2-targeting mAb linked to a TLR8 agonist, is in a Phase I study. Silverback...
...to CSO Valerie Odegard, and promoted SVP of Clinical R&D Naomi Hunder to CMO (see “Silverback...
BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...join co-founder and CMO Samuel Blackman, a pediatric oncologist with experience at multiple biopharmas including Silverback Therapeutics Inc....
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

...Laura Shawver has joined Silverback Therapeutics Inc. as president, CEO and a director. Shawver, who succeeds Peter Thompson...
...Therapeutics Inc. and is a board member of The Clearity Foundation and Relay Therapeutics Inc. Silverback...
...a March series B to bring its innate immunity-activating antitumor mAb into the clinic (see “Silverback...
BioCentury | Mar 12, 2020
Finance

Silverback raises $78.5M series B to send innate immunity activating therapies to clinic

...As Silverback prepares to enter the clinic this year with its lead antibody-based cancer therapy, the...
...combining the anti-HER2 mAb with Silverback’s compound decreased tumor growth compared with either treatment alone. Silverback’s...
...into the clinic. Thompson declined to disclose other programs in Silverback’s pipeline. Root will join Silverback’s...
BioCentury | Mar 14, 2019
Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

...and potently activate myeloid cells, the tumor microenvironment is completely reprogrammed,” Valerie Odegard, CSO of Silverback Therapeutics Inc....
...cells but are replete with myeloid cells. Thompson is co-founder, chairman, president and CEO of Silverback...
...Thompson said Silverback is looking to close a series B later this year. COMPANY PROFILE Silverback Therapeutics Inc....
BioCentury | Sep 28, 2018
Financial News

Silverback announces series A extension

...Cancer and autoimmune company Silverback Therapeutics Inc. (Seattle, Wash.) raised an extension of its series A round on...
...by existing investor OrbiMed. New investors Celgene Corp. (NASDAQ:CELG) and Alexandria Venture Investments also participated. Silverback's...
...developed to treat cancer and fibrosis, with initial data expected next year. Silverback Therapeutics Inc., Seattle, Wash. Chris Lieu Silverback Therapeutics Inc....
Items per page:
1 - 8 of 8
BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

...least two other companies, Bolt Therapeutics Inc. and Silverback Therapeutics Inc. (NASDAQ:SBTX...
...the viral ssRNA detectors TLR7 and TLR8; Silverback’s...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...Shawver’s Silverback raises $242M, while Sigilon brings in $126M   By Paul Bonanos, Associate Editor Three more...
...aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback...
...Sanofi (Euronext:SAN; NASDAQ:SNY). OrbiMed Advisors is Silverback’s largest shareholder, with 35% before the offering.On Friday, Silverback...
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...Biotech to List on HK Main Board”).EcoR1 leads Silverback’s $85M roundInnate immune and cancer company Silverback Therapeutics Inc....
...comprising a HER2-targeting mAb linked to a TLR8 agonist, is in a Phase I study. Silverback...
...to CSO Valerie Odegard, and promoted SVP of Clinical R&D Naomi Hunder to CMO (see “Silverback...
BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...join co-founder and CMO Samuel Blackman, a pediatric oncologist with experience at multiple biopharmas including Silverback Therapeutics Inc....
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

...Laura Shawver has joined Silverback Therapeutics Inc. as president, CEO and a director. Shawver, who succeeds Peter Thompson...
...Therapeutics Inc. and is a board member of The Clearity Foundation and Relay Therapeutics Inc. Silverback...
...a March series B to bring its innate immunity-activating antitumor mAb into the clinic (see “Silverback...
BioCentury | Mar 12, 2020
Finance

Silverback raises $78.5M series B to send innate immunity activating therapies to clinic

...As Silverback prepares to enter the clinic this year with its lead antibody-based cancer therapy, the...
...combining the anti-HER2 mAb with Silverback’s compound decreased tumor growth compared with either treatment alone. Silverback’s...
...into the clinic. Thompson declined to disclose other programs in Silverback’s pipeline. Root will join Silverback’s...
BioCentury | Mar 14, 2019
Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

...and potently activate myeloid cells, the tumor microenvironment is completely reprogrammed,” Valerie Odegard, CSO of Silverback Therapeutics Inc....
...cells but are replete with myeloid cells. Thompson is co-founder, chairman, president and CEO of Silverback...
...Thompson said Silverback is looking to close a series B later this year. COMPANY PROFILE Silverback Therapeutics Inc....
BioCentury | Sep 28, 2018
Financial News

Silverback announces series A extension

...Cancer and autoimmune company Silverback Therapeutics Inc. (Seattle, Wash.) raised an extension of its series A round on...
...by existing investor OrbiMed. New investors Celgene Corp. (NASDAQ:CELG) and Alexandria Venture Investments also participated. Silverback's...
...developed to treat cancer and fibrosis, with initial data expected next year. Silverback Therapeutics Inc., Seattle, Wash. Chris Lieu Silverback Therapeutics Inc....
Items per page:
1 - 8 of 8